Mereo Biopharma (MREO)
NASDAQ:MREO
Want to see MREO full AI Analyst Report?
MREO Stock Chart & Stats
$0.34
-$0.02(-0.40%)
At close: 4:00 PM EST
$0.34
-$0.02(-0.40%)
Day’s Range― - ―
52-Week Range$0.20 - $3.05
Previous CloseN/A
Volume219.93K
Average Volume (3M)5.17M
Market Cap
$49.77M
Enterprise Value$18.69M
Total Cash (Recent Filing)$36.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 18, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding159,618,600
10 Day Avg. Volume9,644,709
30 Day Avg. Volume5,173,780
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.62
Price to Sales (P/S)132.86
P/FCF Ratio-2.14
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue37.37
Enterprise Value/Gross Profit298.92
Enterprise Value/Ebitda-0.48
Forecast
1Y Price Target
$2.33Price Target Upside586.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$23.02M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthZero reported total debt is a durable financial strength for a clinical-stage biotech. It lowers fixed financing costs and covenant risk, preserving optionality to fund trials via partnerships or equity and providing flexibility versus indebted peers during multi-year development programs.
High Gross Margin On RevenueReported low-70% gross margins on existing revenues indicate favorable product economics common to biologics. If programs scale or are partnered, these unit economics can support eventual profitable operations once operating costs are controlled or commercialization begins.
Governance Continuity And Financing FlexibilityReappointment of directors and renewed share-allotment authority provide governance continuity and structural financing flexibility. For a cash-burning clinical-stage company, explicit ability to raise equity through 2029 supports long-term funding options to advance trials and partnerships.
Bears Say
Persistent Cash BurnSustained operating and free cash outflows (~$27M TTM) create a structural funding requirement. Over multiple quarters this forces recurring external financing or partnerships, increases dilution risk, and can delay programs if capital access tightens, pressuring long-term execution.
Minimal Revenue And Large LossesVery low recurring revenue combined with a sizable TTM net loss means operations are not self-sustaining. Until product approvals or material partnership revenues occur, the company relies on external capital, making long-term viability contingent on successful financing or licensing.
Declining Equity Base And Dilution RiskA declining equity base and persistently negative returns highlight repeated capital consumption and likely reliance on new equity issuances. Structurally, this raises dilution risk for shareholders and can constrain strategic flexibility if market conditions or investor appetite weaken.
Mereo Biopharma Group Plc News
MREO FAQ
What was Mereo Biopharma’s price range in the past 12 months?
Mereo Biopharma lowest stock price was $0.20 and its highest was $3.05 in the past 12 months.
What is Mereo Biopharma’s market cap?
Mereo Biopharma’s market cap is $49.77M.
When is Mereo Biopharma’s upcoming earnings report date?
Mereo Biopharma’s upcoming earnings report date is Aug 18, 2026 which is in 67 days.
How were Mereo Biopharma’s earnings last quarter?
Mereo Biopharma released its earnings results on May 12, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.001.
Is Mereo Biopharma overvalued?
According to Wall Street analysts Mereo Biopharma’s price is currently Undervalued.
Does Mereo Biopharma pay dividends?
Mereo Biopharma does not currently pay dividends.
What is Mereo Biopharma’s EPS estimate?
Mereo Biopharma’s EPS estimate is -0.01.
How many shares outstanding does Mereo Biopharma have?
Mereo Biopharma has 159,618,600 shares outstanding.
What happened to Mereo Biopharma’s price movement after its last earnings report?
Mereo Biopharma reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went up 1.653%.
Which hedge fund is a major shareholder of Mereo Biopharma?
Currently, no hedge funds are holding shares in MREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.33 (586.27% Upside)
$2.33 (586.27% Upside)
Blogger Sentiment
Bullish
MREO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 517.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.52%
12-Months-Change
Fundamentals
Return on Equity
-81.25%
Trailing 12-Months
Asset Growth
-40.55%
Trailing 12-Months
Company Description
Mereo Biopharma
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
MREO Stock 12 Month Forecast
Average Price Target
$2.33
▲(586.27% Upside)
Technical Analysis
Ownership Overview
0.81%
Insiders
0.09% Mutual Funds
37.27% Other Institutional Investors
61.48% Public Companies and
Individual Investors